Advancements in Atopic Dermatitis Treatment: Amlitelimab Shows Promising Results
TL;DR Summary
Sanofi's anti-OX40L antibody, amlitelimab, has successfully met the primary endpoint in a Phase IIb trial for atopic dermatitis, showing up to a 61.5% improvement in eczema severity. The detailed data from the trial has paved the way for a Phase III study in the first half of next year, strengthening Sanofi's immunology portfolio. Amlitelimab was acquired by Sanofi through its acquisition of Kymab in 2021.
- Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial Endpoints News
- Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Yahoo Finance
- Sanofi reaps rewards of immunology investment with eczema results MarketWatch
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress GlobeNewswire
- Amlitelimab A Revolutionary Solution for Atopic Dermatitis Best Stocks
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
52%
136 → 65 words
Want the full story? Read the original article
Read on Endpoints News